Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. It operates through the following segments: Midkine Business and Consumer Health Business. The Midkine Business segment deals with Midkine diagnostics and therapeutics for cancer and inflammatory conditions. The Consumer Health Business segment focuses on the research, development, and marketing of hair growth products. The company was founded on October 8, 2004 and is headquartered in Sydney, Australia.
|Market Price at 20-11-2017||$0.02|
|Price to Earnings Ratio||-5.93|
|Market Capitalisation||$428.98 (million)|
|Return on Equity (ROE)||-101.59%|